Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Identification of novel proteins interacting with vascular endothelial growth inhibitor 174 in renal cell carcinoma

Zhao, Qiang, Kun, Duoer, Hong, Baoan, Deng, Xiaohu, Guo, Sheng, Tang, Xingxing, Yang, Yong, Gong, Kan, Li, Qing, Ye, Lin, Jiang, Wen and Zhang, Ning 2017. Identification of novel proteins interacting with vascular endothelial growth inhibitor 174 in renal cell carcinoma. Anticancer Research 37 (8) , pp. 4379-4388. 10.21873/anticanres.11832

PDF - Published Version
Download (4MB) | Preview


Background/Aim: Vascular endothelial growth inhibitor (VEGI) is a multipotential cytokine that plays a role in regulating immunity, anti-angiogenesis, and inhibiting tumor growth. However, the proteins that interact with it are still unknown. In the present study, we examined the proteins which interact with VEGI174 and their expressions in renal cell carcinoma (RCC). Materials and Methods: The proteins that interact with VEGI174 were identified using western blot, pull-down assay, and mass spectrometry. The expressions of VEGI174 and the interacting proteins were examined in RCC and were compared with normal renal tissues using immunochemical staining and RNA-seq respectively. Results: The results of the mass spectrometric analysis showed that ACLY, ENO1, ZIK1, AKR1C3, and MYC may interact with VEGI174. When compared with the TCGA database, the expression level of VEGI174 in RCC was lower than that in normal kidney using RNAseq (p<0.001). The expression levels of ACLY, ENO1, ZIK1, AKR1C3 and MYC in RCC were higher than that in normal kidney (p<0.05, all of above factors). Moreover, immunochemical staining results also showed that the expression level of AKR1C3 in RCC was significantly higher than that in normal kidney (p<0.001) and was also positively correlated with higher RCC stage and grade. Conclusion: Taken together, our findings showed that VEGI174 may interact with ACLY, ENO1, ZIK1, AKR1C3, and MYC. The expression of ACLY, ENO1, AKR1C3 and MYC is increased in RCC. AKR1C3 was a new factor that may correlate with the progression of RCC. The results indicated that VEGI174 has more functions than we currently know in the development and progression of RCC

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: International Institute of Anticancer Research
ISSN: 0250-7005
Date of First Compliant Deposit: 16 February 2018
Date of Acceptance: 9 June 2017
Last Modified: 19 Feb 2018 14:28

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics